Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

0.8906
-0.0194-2.13%
Volume:20.73K
Turnover:18.45K
Market Cap:13.30M
PE:-0.54
High:0.9000
Open:0.8885
Low:0.8885
Close:0.9100
52wk High:4.70
52wk Low:0.8375
Shares:14.94M
Float Shares:12.00M
Volume Ratio:1.83
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-4.13
PE(LYR):-0.57

Loading ...

Lantern Pharma - Reports Lp-300 Pfs Benefit Deepens With Treatment Duration in L858r Lung Cancer

THOMSON REUTERS
·
Jun 02

Lantern Pharma - L858r Nsclc Patients Reached 8.9-Month Median Pfs With Lp-300; Durable Responses Beyond Two Years

THOMSON REUTERS
·
Jun 02

Lantern Pharma posts LP-300 Phase 2 HARMONIC trial presentation in EGFR L858R NSCLC

Reuters
·
Jun 02

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress

TIPRANKS
·
Jun 02

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

Reuters
·
May 19

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for Harmonic™ Phase 2 Trial of Lp-300 in Never-Smokers With Nsclc

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Discontinue Control Arm of the Harmoni Trial and Migrate to Single-Arm Design

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Increase Maximum Lp-300 Treatment Cycles to Eight

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - FDA Raises No Objections to Key Proposed Harmonic Trial Amendments

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Focus Enrollment on Egfr Exon 21 L858r Mutation Patients

THOMSON REUTERS
·
May 19

Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate

Benzinga Earnings
·
May 16

Lantern Pharma Q1 FY26 net loss narrows 27% to USD 3.3 million

Reuters
·
May 16

Lantern Pharma Q1 EPS USD -0.3

THOMSON REUTERS
·
May 16

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
May 16

Promising Penny Stocks To Consider In May 2026

Simply Wall St.
·
May 15

Lantern Pharma Directors Make Bold Insider Moves That Investors Can’t Ignore

TIPRANKS
·
May 15

Lantern Pharma raises capital, plans AI platform spinoff

TIPRANKS
·
May 15

Lantern Pharma director Lee T. Schalop acquires 48,544 shares for $99,999.64

Reuters
·
May 15

Lantern Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
May 14